Saturday, May 09, 2026
In Detail Full day, Saturday, May 09, 2026, Timezone: America/Chicago
1K steps daily after surgery can cut readmissions by 16%: 3 study notes
Mariah Taylor / beckershospitalreview - Each additional 1,000 steps per day a patient walks after surgery is linked to 18% lower odds of complications, 16% lower readmission rates and 6% shorter hospital stays, researchers found. The study, conducted by researchers at Columbus-based Ohio State …
AI Summary: A simple prescription — roughly 1,000 steps per day after surgery — was linked to a 16% reduction in readmissions in recent studies. Researchers suggest wearable step tracking as an inexpensive, scalable recovery aid that encourages mobility, reduces complications, and nudges postoperative care toward behaviourally realistic, low‑tech interventions that actually work.
Health advice is all over social media. Here's how to vet claims
medicalxpress - Health and wellness advice is available in abundance on social media—from trendy to informative to straight-up disinformation—and you're far from alone in seeing it.
AI Summary: Social media is awash with health advice, much of it anecdote masquerading as evidence. Report outlines practical steps to separate useful guidance from nonsense: check original sources, prefer peer‑reviewed studies and guidelines, question sensational claims, and consult clinicians before acting. Because no, a viral post is not a clinical trial.
A new Medicare option for weight loss drugs is coming: Here's what to know
Jackie Fortiér / npr - Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.
AI Summary: Medicare is introducing a new option to expand access to weight‑loss medications for older Americans, outlining eligibility, coverage mechanics and likely impacts on beneficiaries and budgets. The guidance aims to help clinicians and patients navigate coverage decisions and prepares stakeholders for shifts in prescribing patterns and costs as demand for GLP‑1 class drugs remains high.
- Competition, dosing and long-term weight strategies (4)
- Efficacy and safety of GLP‑1s in older adults (3)
- Medicare expansion and coverage landscape (3)
- All Other Stories
Competition, dosing and long-term weight strategies
Efficacy and safety of GLP‑1s in older adults
Medicare expansion and coverage landscape
All Other Stories
UCB bets $2 billion on Candid's T cell engager ambitions
Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...
AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.
Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
Max Gelman / endpoints - There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...
AI Summary: Regulators have agreed to re-examine a previously rejected cell‑therapy application for a rare lymphoma, giving the Atara‑Pierre Fabre program another opportunity at approval. The decision follows additional data and stakeholder engagement, offering the developer a second bite at the apple and patients a renewed, if cautious, hope for a novel treatment pathway.
FDA approves blood test to guide breast cancer therapy
Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …
AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.
- ESMO Breast highlights and expert commentary (4)
- FDA clearances reshape diagnostics and therapies (3)
- Liquid biopsy, mutations and treatment resistance (4)
- All Other Stories
ESMO Breast highlights and expert commentary
FDA clearances reshape diagnostics and therapies
Liquid biopsy, mutations and treatment resistance
All Other Stories
Amwell expects smaller losses in 2026 after Q1 performance
Emily Olsen / healthcaredive - The health technology firm’s results give Amwell “increased confidence” it will meet a long-term goal of achieving positive cash flow from operations in the fourth quarter, CFO Mark Hirschhorn said.
AI Summary: Telehealth provider Amwell posted Q1 results showing better-than-expected customer renewals and retention, helping the company forecast smaller losses despite soft revenue. The results suggest operational improvements are stabilizing the business and give investors a slightly less gloomy view of the telehealth market's near-term prospects.
National study examines genetic testing to inform follow-up care for cancer survivors
medicalxpress - Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those…
AI Summary: A national study has been launched to assess whether genetic testing can refine follow-up care for cancer survivors, tailoring surveillance to individual risk and potentially reducing unnecessary tests. The large-scale effort seeks to integrate genomic data into survivorship plans to better predict late effects and allocate resources to those most likely to benefit.
- Building survivorship standards, care and advocacy (4)
- Conferences, research and personalized cancer survivorship insights (4)
- National genetic-testing study and genomic implications for survivors (4)
- All Other Stories
Building survivorship standards, care and advocacy
Conferences, research and personalized cancer survivorship insights
National genetic-testing study and genomic implications for survivors
All Other Stories
RFK Jr. launches plan to curb antidepressant 'overprescription'
medicalxpress - A new federal initiative aims to curb "overprescribing" of psychiatric medications while emphasizing holistic care.
AI Summary: Robert F. Kennedy Jr. launched a campaign aimed at reducing antidepressant prescribing and helping people taper long-term use, combining policy proposals and public outreach. The initiative challenges current prescribing norms and has provoked debate between advocates for reducing medication dependence and clinicians cautious about abrupt shifts in psychiatric care.
Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
fiercehealthcare - The deal would bring the 40-year-old, publicly traded company under a growth-oriented investment firm with a prior background in healthcare staffing.
AI Summary: Staffing firm Cross Country Healthcare agreed to be taken private in a $437 million deal by private equity buyer Knox Lane, ending its public-company chapter. The acquisition positions the firm for strategic repositioning and could reverberate across hospital staffing markets as investors consolidate workforce services.
Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
fiercehealthcare - The deal, expected to close later this year, is another attempt from the major rural nonprofit system to enter the Minneapolis market. To do so, it plans a $600 million investment into two-hospital North Memorial Health that will help stabilize one financ…
AI Summary: Sanford Health announced a plan to integrate Minnesota-area North Memorial Health with a $600 million investment, creating a combined system aimed at expanding services, streamlining care and gaining scale. The transaction is part of a broader wave of regional healthcare consolidation as systems chase efficiency and market presence.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Gene Therapy, Neuroscience, Pediatric Oncology, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine
More StackHealth